Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 18 | 2026 | 409 | 5.370 |
Why?
|
| Liver Cirrhosis | 12 | 2026 | 910 | 1.500 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2026 | 154 | 1.370 |
Why?
|
| Fatty Liver | 3 | 2025 | 221 | 1.060 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 366 | 0.830 |
Why?
|
| Liver | 6 | 2025 | 1797 | 0.800 |
Why?
|
| Liver Diseases | 3 | 2023 | 379 | 0.780 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 576 | 0.700 |
Why?
|
| Portal System | 1 | 2021 | 34 | 0.680 |
Why?
|
| Collateral Circulation | 1 | 2021 | 41 | 0.660 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 31 | 0.640 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 44 | 0.640 |
Why?
|
| Patient Safety | 1 | 2024 | 442 | 0.600 |
Why?
|
| Duty to Warn | 1 | 2019 | 2 | 0.590 |
Why?
|
| Professional Impairment | 1 | 2019 | 3 | 0.590 |
Why?
|
| Alcoholic Intoxication | 1 | 2019 | 14 | 0.580 |
Why?
|
| Confidentiality | 1 | 2019 | 105 | 0.550 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2018 | 22 | 0.550 |
Why?
|
| Feeding Behavior | 1 | 2023 | 705 | 0.540 |
Why?
|
| Community Health Services | 1 | 2018 | 87 | 0.520 |
Why?
|
| Global Health | 2 | 2023 | 626 | 0.510 |
Why?
|
| Electric Impedance | 1 | 2017 | 72 | 0.510 |
Why?
|
| Anthropometry | 1 | 2017 | 187 | 0.500 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 141 | 0.490 |
Why?
|
| Patient Compliance | 1 | 2019 | 465 | 0.490 |
Why?
|
| Alcoholism | 1 | 2019 | 244 | 0.490 |
Why?
|
| Acculturation | 1 | 2016 | 60 | 0.480 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3033 | 0.480 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 85 | 0.470 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 93 | 0.470 |
Why?
|
| Arteriolosclerosis | 1 | 2015 | 2 | 0.460 |
Why?
|
| Spleen | 1 | 2016 | 257 | 0.460 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 3803 | 0.460 |
Why?
|
| Humans | 39 | 2026 | 130422 | 0.460 |
Why?
|
| Middle Aged | 18 | 2026 | 28383 | 0.460 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 134 | 0.460 |
Why?
|
| Mexican Americans | 1 | 2016 | 162 | 0.450 |
Why?
|
| Adult | 16 | 2026 | 31127 | 0.440 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 67 | 0.440 |
Why?
|
| Carcinoma | 1 | 2017 | 284 | 0.430 |
Why?
|
| Adipose Tissue | 1 | 2017 | 495 | 0.420 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 249 | 0.420 |
Why?
|
| Internship and Residency | 1 | 2024 | 1215 | 0.410 |
Why?
|
| Mass Screening | 1 | 2019 | 805 | 0.400 |
Why?
|
| Risk Factors | 10 | 2024 | 10942 | 0.400 |
Why?
|
| Exercise | 4 | 2023 | 859 | 0.390 |
Why?
|
| Prevalence | 6 | 2022 | 2685 | 0.390 |
Why?
|
| Obesity | 5 | 2024 | 2379 | 0.380 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 420 | 0.380 |
Why?
|
| Prebiotics | 1 | 2012 | 28 | 0.370 |
Why?
|
| Male | 19 | 2026 | 64527 | 0.350 |
Why?
|
| Metagenome | 1 | 2012 | 142 | 0.350 |
Why?
|
| Female | 21 | 2026 | 70285 | 0.350 |
Why?
|
| End Stage Liver Disease | 2 | 2026 | 193 | 0.330 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 326 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 743 | 0.330 |
Why?
|
| Life Style | 3 | 2022 | 445 | 0.320 |
Why?
|
| Probiotics | 1 | 2012 | 224 | 0.310 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 343 | 0.290 |
Why?
|
| Biomarkers | 5 | 2026 | 3394 | 0.290 |
Why?
|
| Weight Loss | 2 | 2023 | 525 | 0.280 |
Why?
|
| Intestines | 1 | 2012 | 590 | 0.280 |
Why?
|
| United States | 8 | 2026 | 11827 | 0.280 |
Why?
|
| Hypertension | 2 | 2021 | 1352 | 0.270 |
Why?
|
| Helicobacter pylori | 1 | 2017 | 1362 | 0.270 |
Why?
|
| Helicobacter Infections | 1 | 2017 | 1302 | 0.270 |
Why?
|
| Diet | 3 | 2023 | 1098 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2026 | 6423 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 877 | 0.250 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 81 | 0.250 |
Why?
|
| Gastroenterologists | 1 | 2026 | 13 | 0.240 |
Why?
|
| Biopsy | 2 | 2020 | 1239 | 0.240 |
Why?
|
| Alanine Transaminase | 2 | 2016 | 157 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1443 | 0.240 |
Why?
|
| Aged | 9 | 2026 | 20894 | 0.220 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2025 | 29 | 0.220 |
Why?
|
| Fibrosis | 3 | 2022 | 419 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 2919 | 0.210 |
Why?
|
| Fast Foods | 1 | 2023 | 25 | 0.200 |
Why?
|
| Odds Ratio | 2 | 2016 | 1215 | 0.200 |
Why?
|
| Quality of Life | 2 | 2026 | 2071 | 0.190 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 99 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 331 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 343 | 0.190 |
Why?
|
| Cluster Analysis | 1 | 2023 | 417 | 0.180 |
Why?
|
| Young Adult | 4 | 2018 | 9995 | 0.180 |
Why?
|
| Disease Management | 2 | 2018 | 559 | 0.180 |
Why?
|
| Hypertension, Portal | 2 | 2021 | 80 | 0.180 |
Why?
|
| Safety-net Providers | 2 | 2020 | 86 | 0.180 |
Why?
|
| Palliative Care | 1 | 2026 | 443 | 0.180 |
Why?
|
| Public Health | 1 | 2023 | 272 | 0.170 |
Why?
|
| Observer Variation | 2 | 2025 | 312 | 0.170 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 42 | 0.170 |
Why?
|
| Actigraphy | 1 | 2021 | 53 | 0.170 |
Why?
|
| Primary Health Care | 2 | 2024 | 769 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 4002 | 0.160 |
Why?
|
| Incidence | 2 | 2018 | 3330 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 551 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 300 | 0.150 |
Why?
|
| Linear Models | 1 | 2021 | 688 | 0.150 |
Why?
|
| Health Behavior | 1 | 2022 | 388 | 0.150 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 40 | 0.150 |
Why?
|
| Rooming-in Care | 1 | 2018 | 1 | 0.140 |
Why?
|
| Safety | 1 | 2019 | 213 | 0.140 |
Why?
|
| Hepatic Encephalopathy | 1 | 2019 | 82 | 0.140 |
Why?
|
| Risk | 1 | 2020 | 729 | 0.140 |
Why?
|
| Urban Health | 1 | 2018 | 83 | 0.140 |
Why?
|
| Disease Progression | 2 | 2026 | 2205 | 0.140 |
Why?
|
| Communicable Diseases | 1 | 2020 | 159 | 0.130 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 81 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2025 | 963 | 0.130 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 20 | 0.130 |
Why?
|
| Latin America | 1 | 2017 | 101 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 125 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6781 | 0.130 |
Why?
|
| Age Distribution | 1 | 2018 | 424 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2024 | 812 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 220 | 0.130 |
Why?
|
| Food Supply | 1 | 2017 | 91 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 222 | 0.130 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 39 | 0.120 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 103 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2022 | 17614 | 0.120 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 169 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 555 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 456 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2018 | 251 | 0.110 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 8 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2026 | 3815 | 0.100 |
Why?
|
| Hydrothorax | 1 | 2014 | 10 | 0.100 |
Why?
|
| Length of Stay | 1 | 2020 | 1395 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2019 | 806 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 1005 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1377 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2024 | 3682 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2018 | 698 | 0.090 |
Why?
|
| Logistic Models | 1 | 2016 | 1799 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 1395 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1473 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2026 | 1485 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 1605 | 0.080 |
Why?
|
| Diarrhea | 1 | 2012 | 312 | 0.080 |
Why?
|
| Age Factors | 1 | 2016 | 2835 | 0.080 |
Why?
|
| Hospitalization | 1 | 2019 | 1927 | 0.080 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2012 | 216 | 0.080 |
Why?
|
| Texas | 1 | 2018 | 3626 | 0.070 |
Why?
|
| Clostridium Infections | 1 | 2012 | 249 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 449 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 326 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2110 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3388 | 0.070 |
Why?
|
| Time Factors | 1 | 2018 | 6190 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1125 | 0.070 |
Why?
|
| Prognosis | 1 | 2017 | 4894 | 0.070 |
Why?
|
| Chile | 1 | 2025 | 25 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8493 | 0.060 |
Why?
|
| Prednisolone | 1 | 2025 | 70 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2021 | 90 | 0.040 |
Why?
|
| Menopause | 1 | 2021 | 86 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 146 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 695 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1258 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 96 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 154 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2298 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2024 | 1676 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 366 | 0.030 |
Why?
|
| Adolescent | 1 | 2015 | 20754 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 332 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 439 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 429 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1065 | 0.030 |
Why?
|
| Child | 1 | 2015 | 26165 | 0.030 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2014 | 16 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1587 | 0.030 |
Why?
|
| Diuretics | 1 | 2014 | 157 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5069 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1231 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2546 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1136 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12860 | 0.010 |
Why?
|